Clinical TrialKetamineKetaminePlaceboCompleted
CAP-Ketamine for Antidepressant Resistant PTSD
The purpose of this study is to test the safety and efficacy of repeated doses of ketamine as compared to placebo, in reducing symptoms of Posttraumatic Stress Disorder (PTSD) in an active duty military and Veteran population.
Target Enrollment
Not specified
Study Type
Phase II interventional
Design
Randomized
Registry
Study Arms & Interventions
Standard Dose
experimentalKetamine 0.5 mg/kg administered via 8 intravenous infusions, twice weekly.
Interventions
- Ketamine0.5 mg/kgvia IV• twice weekly• 8 doses total
8 infusions total
Low Dose
experimentalKetamine 0.2 mg/kg administered via 8 intravenous infusions, twice weekly.
Interventions
- Ketamine0.2 mg/kgvia IV• twice weekly• 8 doses total
8 infusions total
Placebo
placeboIntravenous placebo (normal saline) administered twice weekly.
Interventions
- Placebovia IV• twice weekly• 8 doses total
normal saline
Primary Results(1 publication)
Participants
Adverse Events (from all publications)
| Arm / Group | n | Any TEAE | Severe | Serious | Discont. |
|---|---|---|---|---|---|
| Standard Doseexperimental | 51 | 46(90.2%) | — | — | — |
| Low Doseexperimental | 53 | 46(86.8%) | — | — | — |
| Placeboplacebo | 54 | 45(83.3%) | — | — | — |
* Based on Table S1: # Subjects Reporting 46. Total AEs reported was 138.
* Based on Table S1: # Subjects Reporting 46. Total AEs reported was 154.
* Based on Table S1: # Subjects Reporting 45. Total AEs reported was 110.